Anlotinib to Malignant Brainstem Glioma

A Phase II Study of Anlotinib Combined With Radiation in Patients With Malignant Brainstem Glioma

This study is a single-arm, open-label, phase II study of anlotinib combined with radiation in the treatment of patients with malignant brainstem glioma. Twenty five patients will be enrolled in the study who is diagonsis with malignant brainstem glioma. The primary objective includes disease control rate (DCR), the role of antinib combined with radiotherapy in improving quality of life and 6-month progression-free survival rate. The secondary objective include overall survival (OS), toxicity profile. Exploratory objectives include the use of plasma specimens and cerebrospinal fluid (if possible) to detect biomarkers predicting the efficacy of anlotinib.

Anlotinib to Malignant Brainstem Glioma

Recruitment

Summary

Participation Requirements

Description

Tracking Information